Author

M. H. Barcellos-Hoff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Combes· 1 shared A. Lazar· 1 shared A. Linge· 1 shared H. Martinez-Ruiz· 1 shared I. Cuartas· 1 shared I. Guix· 1 shared J. Gkantalis· 1 shared J. Moore· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Combes

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade

J. Moore, J. Gkantalis, I. Guix, W. Chou, K. Yuen, A. Lazar, M. H. Spitzer, A. Combes, M. H. Barcellos-Hoff

This study identifies a biomarker, {beta}Alt, that predicts immune checkpoint blockade response in cold tumors by integrating TGF{beta} signaling, DNA repair, and immune context signatures.

bioRxiv · Mar 6, 2024 · PreprintCancer Biology

Subjugation of TGFβ Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End-Joining

Q. Liu, L. Ma, T. Jones, L. Palomero, M. A. Pujana, H. Martinez-Ruiz, P. Ha, J. Murnane, I. Cuartas, J. Seoane, M. Baumann, A. Linge, M. H. Barcellos-Hoff

This study shows HPV-positive HNSCC cells lose TGFβ signaling, shifting DNA repair from homologous recombination to alternative end-joining, increasing PARP inhibitor sensitivity.

Clinical Cancer Research · Dec 3, 2018Peer-reviewedCancer Biology